Grifols (NASDAQ:GRFS) Stock Rating Upgraded by Wall Street Zen

Grifols (NASDAQ:GRFS) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. lowered their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

Grifols Price Performance

GRFS opened at $7.58 on Friday. The firm has a 50 day moving average price of $8.92 and a 200-day moving average price of $9.15. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.51 and a quick ratio of 0.88.

Hedge Funds Weigh In On Grifols

Several large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in shares of Grifols by 21.7% in the first quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock worth $3,461,000 after purchasing an additional 86,768 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Grifols in the 1st quarter worth $184,000. Goldman Sachs Group Inc. boosted its holdings in Grifols by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after buying an additional 80,507 shares during the period. JPMorgan Chase & Co. increased its stake in Grifols by 13.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,888,176 shares of the biotechnology company’s stock worth $17,069,000 after buying an additional 219,724 shares in the last quarter. Finally, Vinva Investment Management Ltd purchased a new stake in Grifols in the 2nd quarter worth $256,000.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.